Corbus Pharmaceuticals Holdings is focused on the development of immune modulators that will have application in disease states spanning from immuno-oncology to fibrosis. Co.'s pipeline includes anti-integrin monoclonal antibodies that block activation of Transforming growth factor B (TGFB) and small molecules that activate or inhibit the endocannabinoid system. Co.'s pipeline includes: anti-integrin monoclonal antibodies for the treatment of cancer and fibrosis that inhibit the activation of TGFB; cannabinoid receptor type 1 inverse agonists designed to treat obesity and related metabolic diseases; and lenabasum, a synthetic, oral molecule that activates cannabinoid receptor type 2. The CRBP stock yearly return is shown above.
The yearly return on the CRBP stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CRBP annual return calculation with any dividends reinvested as applicable (on ex-dates).
|